## **10/569797** IAPS Rec'd PCT/PTO 27 FEB 2006

## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Intern	ational	Application No.	:	PCT/DE2004/001897						
Intern	ational	Filing Date	:	26 August 2004 (26.08.2004)						
Priori	ty Date	(s) Claimed	:	26 August 2003 (26.08.2003)						
Appli	cant(s)	(DO/EO/US)	:	Uwe FIEBIG, et al.						
	Title: INDUCTION OF ANTIVIRAL NEUTRALIZING ANTIBODIES IN HUMANS AND ANIMALS									
INFO	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98									
P.O. E	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450									
Sir:	Sir:									
and 1.	This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:									
Timing and Fees										
$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:									
		within three months ounder § 1.53(d);	of the filing date	e of a national application other than a CPA						
	$\boxtimes$	within three months application; OR	of the actual f	filing date of the national phase of a PCT						
		before the mailing of RCE).	a first substanti	ive office action (including after filing of an						
		37 C.F.R. § 1.97(c), th ied in 37 C.F.R. § 1.97		disclosure statement is filed after the periods the mailing date of:						
		a final rejection unde termination of prosec a notice of allowance	ution, e.g. Ex I	Parte Quayle, M.P.E.P § 609(B)(2); OR						

		is acco	inpanied by.
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § $1.17(p)$ .
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a n	otice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).
Statem	ents Un	der 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	Material	<u>s</u>	
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form y the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$		of materials listed but not attached were cited in an international search dated September 15, 2005.
		Not rec	quired by 37 CFR § 1.98.
		Copies	of the materials listed are attached (except for the foregoing).

Non-English	Language References
$\boxtimes$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	X = document of particular relevance when it is taken alone     Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art
	O = non-written disclosure P = intercalated document
	T = document cited to understand the theory or principle underlying the invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
	Translation of other relevant information on foreign search report
Other Inform	ation
Payment of I	Gees Due (If Any):
A che	eck for \$ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/gent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: GULDE-0068

Date: February 27, 2006

AJZ:ssr

Please typa a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Substitute	for form 1449A/PTO				of information unless it contains a valid OMB control num Complete if Known
				Application Number	USNP of PCT/DE2004/001897
			CLOSURE	Filing Date	26 August 2004 (26.08.2004)
STAT	EMENT BY	Y AF	PPLICANT	First Named Inventor	Uwe FIEBIG, et al.
				Group Art Unit	unknown
	(use as many she	ets as	necessary)	Examiner Name	unknown
Sheet	1	of	2	Attorney Docket Number	GULDE-0068

		U.S. Patent Docur	nent			
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY	
/SS/	001	2003/108560	A1	GROGAN, ET AL.	06-12-2003	
	002	6,630,144	B1	HART, ET AL.	10-07-2003	
J.	003	5,124,255	A	BOLLING, ET AL.	06-23-1992	
V	004	2002/151473	A1	BAISTED, ET AL.	10-17-2002	
/88/	005	2004/096972	A1	AUDIT, ET AL.	05-20-2004	
			-			
			+			

					FOREIG	N PATENT DOCUMENTS			
l				Foreign Patent Docum	nent		Date of Publication of	Pages, Columns, Lines, Where Rakwant	
Exemi Initial		Cita No.'	Office3	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T*
/SS	S/	006	wo	02/079239		U.S. ARMY MED. RESEARCH INST., ET AL.	10-10-2002		001
-		007	wo	01/16183		U.S. ARMY MED. RESEARCH INST., ET AL.	03-08-2001		002
		008	FR	2 586 427	Α	PASTEUR INST	02-27-1987		
		009	EP	0 331 961	Α	ABBOTT LABORATORIES	09-13-1989		003
1	,	010	wo	98/20036	Α	GENENTECH, INC.	05-14-1998		004
	<u>,                                     </u>	011	DE	199 57 838	A1	HEINRICH-PETTE INST	06-13-2001		
/80	3/	012	FR	2 832 424	Α	GENETHON III	05-23-2003		005

Signature Considered Considered	Examiner Signature	/Stuart Snyder/	Date Considered	05/22/2008	
---------------------------------	-----------------------	-----------------	--------------------	------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique clation designation number. <sup>2</sup> See attached Kinds of U.S. Platent Documents. <sup>3</sup> Enter Office that issued the document by the horistic code (WPO Standard S.T.). <sup>4</sup> For Japperes platent documents, he indication of the year of the ringer of the Standard representations in uniform of the patient document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English in language Translation is attached. Number offers to English sunging corresponding family member.

Burdan Neur Statement: This form is estimated to take 2.0 hours to complete Time will very depending upon the needs of the including case. Any comments on the amount of imme you are required to complete this form should be sent to the Cifer information Coffeer. U.S. Peter and Trademark.

Time, Washington, Dic 20231. DO NOT SEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450. Assarding AV 2231-1450.

## !APS Roc'd PCT/PTO 27 FEB 2006

10/569797

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute fo	or form 1449A/PTO				Complete if Known
INFOR	MATION	DIE.	CLOSURE	Application Number	USNP of PCT/DE2004/001897
				Filing Date	26 August 2004 (26.08.2004)
SIAII	-MENIR	r Al	PPLICANT	First Named Inventor	Uwe FIEBIG, et al.
				Group Art Unit	unknown
(4	ise as many she	ets as	necessary)	Examiner Name	unknown
Sheet	2	of	2	Attorney Docket Number	GULDE-0068

		NON PATENT LITERATURE DOCUMENTS	
xeminar Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the erticle (when appropriata), title of the item (book, megazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т,
/SS/	013	DATABASE EBI [ONLINE] 01 AUGUST 1990; XP002341810	
	014	FIEBIG U ET AL: "NEUTRALIZING ANTIBODIES AGAINST CONSERVED DOMAINS OF 115E OF PORCINE ENDOGENOUS RETROVIRUSES: BASIS FOR A VACCINE FOR XENOTRANSPLANTATION? VIROLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 307, 10. 2, 15 MARCH 2003, PAGES 406-413, XP002269727; ISSN: 0042-6822	
V	015	DATABASE EMBL [ONLINE], 01 MAY 2000, XP002341811	
755/	016	DATABASE EBI [ONLINE], 13 AUGUST 1987, XP002341812	
			_
			-
			_
-			-
			_

Examiner Signature	/Stuart Snyder/	Date Considered	05/22/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden flow: Statement: This form is estimated to take 2.0 hours to complete. There all very depending upon the needs of the indicidate lass, Any comments on the amount of time you are recisived to complete this from should be sent to take Gord Individual Officer, U.S. Parted and Trademint. Office, Washington, DC 2021; DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. box 1450. Naturation, V. 22231-13